|1.||Dehydration (Water Stress)
|1.||Vesikari, Timo: 20 articles (12/2014 - 10/2004)|
|2.||Parashar, Umesh D: 19 articles (12/2015 - 05/2003)|
|3.||Glass, Roger I: 13 articles (05/2012 - 02/2002)|
|4.||Estes, Mary K: 12 articles (08/2015 - 06/2004)|
|5.||Freedman, Stephen B: 12 articles (01/2015 - 04/2006)|
|6.||Payne, Daniel C: 11 articles (12/2015 - 02/2010)|
|7.||Nakagomi, Osamu: 11 articles (09/2015 - 08/2005)|
|8.||Jiang, Xi: 11 articles (07/2015 - 02/2005)|
|9.||Enjuanes, Luis: 11 articles (01/2015 - 05/2002)|
|10.||DiNubile, Mark J: 11 articles (08/2012 - 01/2006)|
09/01/2006 - "These 2 vaccines have been shown to have an excellent safety profile in clinical trials and are highly effective in protecting infants against severe manifestations of Rotavirus gastroenteritis. "
11/01/2012 - "Two human group A rotavirus (RVA) vaccines are available and highly effective in preventing severe gastroenteritis caused by all commonly circulating human RVA genotypes. "
01/11/2012 - "Both vaccines were highly effective in preventing cases and hospital admissions in children due to rotavirus gastroenteritis."
06/01/2011 - "RIX4414 was highly efficacious against severe rotavirus gastroenteritis caused by the circulating wild-type rotavirus (G1 and non-G1) when coadministered with routine EPI vaccines including OPV."
11/01/2010 - "Two attenuated oral vaccines were licensed in Europe in 2006 and have proven effective against severe rotavirus gastroenteritis in infants, yet few countries have implemented vaccination. "
08/11/2014 - "Live attenuated rotavirus vaccines are highly effective in preventing severe rotavirus gastroenteritis. "
01/01/2008 - "These new safe and effective rotavirus vaccines offer the best hope of reducing the toll of acute rotavirus gastroenteritis in both developed and developing countries."
04/20/2007 - "These new safe and effective rotavirus vaccines offer the best hope of reducing the toll of acute rotavirus gastroenteritis in both developed and developing countries."
02/01/2005 - "New safe and effective rotavirus vaccines offer the best hope of reducing the toll of acute rotavirus gastroenteritis in both developed and developing countries."
01/01/2013 - "Infant rotavirus vaccines have been licensed in Europe and provide excellent protection against severe gastroenteritis, but are not widely implemented due to the perceived benign character of rotavirus disease and unfavourable cost-effectiveness. "
10/01/2007 - "ORS are the only life-saving treatment for gastroenteritis, which has proved its efficacy for the past 50 years: it is time to use it on a routine basis."
06/01/2001 - "ORS has led to improved outcome of acute gastroenteritis in both industrialised and developing countries. "
11/01/2010 - "Pediatricians in Lebanon are aware of the importance of ORS and the positive role of breastfeeding in acute gastroenteritis. "
10/01/2007 - "Parents should be aware of the risks of gastroenteritis in infants, also parents should know how to use ORS. "
08/01/2004 - "Guidelines for efficacious use of ORS in the management of acute gastroenteritis and short gut syndrome are also provided."
12/01/2010 - "In conclusion, RotaTeq is a generally well tolerated vaccine that has efficacy against the five most prevalent serotypes of rotavirus in Europe and provides sustained efficacy over the main risk period for rotavirus gastroenteritis in infants and children, reducing hospitalizations and emergency department visits by decreasing the incidence and severity of illness."
06/18/2010 - "In conclusion, RotaTeq is a generally well tolerated vaccine that has efficacy against the five most prevalent serotypes of rotavirus in Europe and provides sustained efficacy over the main risk period for rotavirus gastroenteritis in infants and children, reducing hospitalizations and emergency department visits by decreasing the incidence and severity of illness."
12/01/2010 - "The protective efficacy of RotaTeq has been evaluated in terms of its effects on the incidence of rotavirus gastroenteritis and on healthcare resource use. "
06/18/2010 - "The protective efficacy of RotaTeq has been evaluated in terms of its effects on the incidence of rotavirus gastroenteritis and on healthcare resource use. "
04/27/2012 - "Efficacy of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), against severe rotavirus gastroenteritis (RVGE) was evaluated in two double-blind, placebo-controlled, multicenter Phase III clinical trials conducted in GAVI-eligible countries in Africa (Ghana, Kenya, and Mali) and in Asia (Bangladesh and Vietnam) from March 2007 through March 2009. "
09/01/2010 - "Results of phase III studies in Europe, Latin America, and Asia have shown that Rotarix offers sustained high protection against severe rotavirus gastroenteritis during the first 2 years of life, when disease burden is highest, with broad protection demonstrated against each of the 5 main rotavirus types that circulate globally (G1, G2, G3, G4, and G9). "
10/09/2009 - "This study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix) during the first 2 years of life in Asian infants from high-income countries. "
08/01/2009 - "The protective efficacy against severe rotavirus gastroenteritis afforded by Rotarix is consistently better against strains that share with RIX4414 both G and P serotypes (i.e., G1P), or only P serotype (i.e., G3P, G4P and G9P). "
12/01/2009 - "It provided 85-96% protection against severe rotavirus gastroenteritis caused by G1 and non-G1 serotypes in Latin American and European clinical trials; and of public health importance, Rotarix reduced hospitalizations of all-cause gastroenteritis by 40 and 75%, respectively. "
11/24/2007 - "We aimed to assess the efficacy of the oral live attenuated human rotavirus vaccine Rotarix (RIX4414) for prevention of rotavirus gastroenteritis in European infants during their first 2 years of life. "
|6.||rhesus rotavirus vaccineIBA
07/01/2000 - "RRV-TV was also shown to be 75% protective against very severe gastroenteritis in northern Brazil. "
02/01/1998 - "RRV-TV has similar overall efficacy to RRV-S1, but provides greater protection against gastroenteritis caused by rotavirus strains of serotypes other than G1. "
05/01/1999 - "Stool specimens from 1528 episodes of acute gastroenteritis (805 in the placebo group and 723 in the RRV-TV vaccine group) were tested for astrovirus with a sensitive reverse transcription-polymerase chain reaction (RT-PCR) assay and positive results were confirmed by Southern hybridization using probes specific for astrovirus serotypes 1 and 2. Astroviruses were detected in 144 (9%) episodes of gastroenteritis; 92% of the findings were serotype 1 and 6% were serotype 2. The astrovirus peak season was in winter. "
10/01/1997 - "During the first year of surveillance, the estimates of vaccine efficacy (with 95% confidence interval) for preventing rotaviral gastroenteritis were 50% (26, 67) for RRV-TV and 29% (-1, 50) for RRV-S1. "
08/01/1994 - "Efficacy of rhesus rotavirus vaccine MMU-18006 against gastroenteritis due to serotype 1 rotavirus."
04/01/1985 - "Protection against rotavirus-induced gastroenteritis in a murine model by passively acquired gastrointestinal but not circulating antibodies."
06/01/2008 - "This study established radioimmunoprecipitation (RIP) assays using labeled G1P, G2P, and G4P human rotaviruses to examine the spectrum and duration of rotavirus antibodies in sera collected sequentially for 18-36 months from 27 children after hospitalization for primary rotavirus gastroenteritis. "
08/01/2012 - "Finally, there is a section on the possible use of oral antibodies given as food to prevent diseases such as infantile gastroenteritis. "
07/01/2010 - "This work is the first to establish a correlation between the high seroprevalence of specific Aichi virus antibodies, clinical presentation, and a high frequency of isolation of Aichi virus by genomic characterization in stools of children suffering from gastroenteritis. "
10/01/2008 - "Antibodies to A4-Fla2 and Fla-X were significantly more frequent in IBS patients with antecedent gastroenteritis compared to non-postinfectious IBS patients (P = 0.002 and P = 0.012). "
|8.||Ondansetron (Zofran)FDA LinkGeneric
03/01/2012 - "We aimed to determine whether increasing ondansetron usage is associated with improved outcomes in children with gastroenteritis. "
10/01/2013 - "Although administrayion of oral ondansetron in gastroenteritis could decrease failure of ORT, it seems that further well-conducted clinical studies are needed to determine effects of oral ondansetron precisely."
10/01/2013 - "In a single center, randomized, double blind, controlled trial, the effect of oral ondansetron was compared with placebo on 176 patients between 1 and 10 years old with acute gastroenteritis. "
12/01/2010 - "Ondansetron dosing in pediatric gastroenteritis: a prospective cohort, dose-response study."
04/20/2006 - "We conducted a double-blind trial to determine whether a single oral dose of ondansetron, an antiemetic, would improve outcomes in children with gastroenteritis. "
07/01/1983 - "The efficacy of the morantel sustained release bolus in controlling parasitic gastroenteritis in 153 first-season grazing cattle was assessed in three separate field trials conducted in Normandy, France. "
07/01/1983 - "The efficacy of the morantel sustained release bolus system for the control of parasitic gastroenteritis in calves was evaluated in the Netherlands. "
01/01/1992 - "The efficacy of the Paratect Flex-Bolus for the control of parasitic gastroenteritis in calves was evaluated in a field experiment in the Swiss midland region. "
07/01/1985 - "In the course of studies on the control of bovine parasitic gastroenteritis in south west Scotland using a morantel sustained release bolus the populations of trichostrongyle infective larvae on herbage were monitored over a two-year period. "
05/01/1984 - "[Comparative trials of parasitic gastroenteritis control in calves and 2d-season cattle using a morantel long-term bolus]."
|10.||Immunoglobulin A (IgA)IBA
01/01/2014 - "Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis: analysis of clinical trials of human rotavirus vaccine."
04/27/2012 - "The efficacy of PRV against severe rotavirus gastroenteritis was 42.7% through the entire follow-up period; serum anti-rotavirus IgA response was 78.1%. "
06/01/2003 - "IgA seroconversion occurred in 57%, 70%, and 50%, respectively, of children with rotavirus gastroenteritis; in rotavirus-uninfected children, 1 child each seroconverted to the different rNSP4s. "
05/01/1996 - "Dogs with nonspecific gastroenteritis had a significantly higher concentration of IgA-containing cells than the other groups of dogs had. "
08/01/1990 - "[Fecal IgA antibody against rotavirus and clinical manifestations of acute viral gastroenteritis in children]."
|1.||Fluid Therapy (Oral Rehydration Therapy)
01/01/1998 - "The best treatment of the infant acute gastroenteritis, when it is applied at home, is oral rehydration. "
11/01/2015 - "In conclusion, there is strong and solid proof of efficacy of probiotics as active treatment of gastroenteritis in addition to rehydration. "
01/01/2011 - "To determine if rapid rather than standard intravenous rehydration results in improved hydration and clinical outcomes when administered to children with gastroenteritis. "
07/01/2003 - "The clinical pathway utilizing rapid rehydration in children moderately dehydrated from gastroenteritis is effective in reducing admission rates and lengths of stay in the ED."
07/01/2003 - "To determine in the Emergency Department (ED) the efficacy of a clinical pathway using rapid rehydration for children moderately dehydrated as a result of acute gastroenteritis. "
|2.||Drug Therapy (Chemotherapy)
08/01/2009 - "We linked the study cohort to registries to obtain data on malignancies, chemotherapy (yes/no), and main comorbidities diagnosed before Salmonella/Campylobacter gastroenteritis. "
06/01/2006 - "Four babies were exposed to chemotherapy during the first trimester, one of them had low birth weight and floating thumb malformation, two of them had only low birth weight, and one was born healthy, but died at 3 months of age as a result of severe gastroenteritis. "
02/01/2006 - "Seven months postcompletion of chemotherapy, he developed signs of gastroenteritis and septicaemia. "
04/01/2004 - "Epidemiologic profile of symptomatic gastroenteritis in pediatric oncology patients receiving chemotherapy."
01/28/2000 - "[Computerized tomography detection of portal vein air accumulation in severe gastroenteritis during chemotherapy]."
|3.||Traditional Medicine (Folk Remedies)
06/01/1980 - "A folk medicine remedy for gastroenteritis."
11/01/2014 - "In folk medicine it is used in gastroenteritis, hepatorenal and in brain anomalies. "
07/01/2014 - "koreana) has been used in the treatment of inflammatory diseases, such as acute gastroenteritis and aches, in Korean folk medicine and has been reported to have a number of biological activities, such as anti-inflammatory activity and the promotion of angiogenesis. "
10/01/2015 - "Chev (Combretaceae) is a medicinal plant used in folk medicine in the management of pain, rheumatic condition, gastroenteritis and as a tranquilizer in psychotic disorder. "
01/01/2010 - "Psidium guajava L., Myrtaceae, is used widely in traditional medicine for the treatment of diarrhoea, dysentery, gastroenteritis, stomachaches, and indigestion. "
|4.||Length of Stay
09/01/2008 - "The scoring system was valuable in predicting a longer length of stay and the need for intravenous fluid rehydration for children with symptoms of acute gastroenteritis."
01/01/2010 - "On average, length of stay for each admission for gastroenteritis and dehydration for children in poverty was 1.3 times that for high-income children (p < 0.01). "
12/01/1998 - "The application of fast-tracking decreased ED length of stay and improved patient satisfaction in patients presenting with allergy, dyspepsia, upper airway infection, minor laceration, and soft tissue injury, but not in patients with gastroenteritis, urinary tract infection, hypertension, and urolithiasis. "
|5.||Home Parenteral Nutrition